Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer

NCT00010218 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00010218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00010218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2001
Completion date
January 31, 2006
Enrollment
55 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer